Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Share-based Compensation: 2009-2025

Historic Share-based Compensation for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $39.1 million.

  • UNITED THERAPEUTICS's Share-based Compensation fell 6.24% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.7 million, marking a year-over-year increase of 1.57%. This contributed to the annual value of $144.0 million for FY2024, which is 268.29% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Share-based Compensation stood at $39.1 million, which was up 3.44% from $37.8 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Share-based Compensation ranged from a high of $65.5 million in Q2 2022 and a low of -$21.1 million during Q1 2022.
  • In the last 3 years, UNITED THERAPEUTICS's Share-based Compensation had a median value of $27.0 million in 2024 and averaged $26.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first slumped by 152.62% in 2022, then surged by 979.17% in 2023.
  • UNITED THERAPEUTICS's Share-based Compensation (Quarterly) stood at $44.7 million in 2021, then soared by 44.97% to $64.8 million in 2022, then plummeted by 74.38% to $16.6 million in 2023, then soared by 62.65% to $27.0 million in 2024, then declined by 6.24% to $39.1 million in 2025.
  • Its Share-based Compensation stands at $39.1 million for Q3 2025, versus $37.8 million for Q2 2025 and $31.8 million for Q1 2025.